- Home
- ACRS vs FAX Comparison
ACRS vs FAX Comparison
Compare ACRS & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | FAX |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 532.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRS | FAX |
|---|---|---|
| Price | $3.89 | $12.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $10.36 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 212.4K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $12.57 |
| 52 Week High | $6.60 | $16.37 |
Technical Indicators
Market Signals| Indicator | ACRS | FAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 46.62 |
| Support Level | $3.18 | $12.59 |
| Resistance Level | $4.67 | $12.99 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 72.03 | 75.95 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.